Press Releases

WASHINGTON, D.C. – Rep. Earl L. “Buddy” Carter (R-GA) today celebrated passage of the Senate companion to his bipartisan bill, the FDA Modernization Act 3.0.

This bill will require the Food and Drug Administration (FDA) to fully implement the FDA Modernization Act 2.0, signed into law in 2022, ensuring that safe and effective treatments are developed for patients using advanced and innovative non-animal testing methods.

The bill now heads to the House for consideration. 

“It is inhumane to rely solely on animal testing of medical products when other, harmless methods exist that are more predictive of human outcomes. The FDA Modernization Act 2.0, and today’s vote by the Senate, have paved the way for modernizing the FDA’s testing methods. This bill will accelerate innovation and get safer, more effective drugs to market quickly by cutting unnecessary red tape,” said Rep. Carter. “There is no reason for the House to delay its vote on this necessary, bipartisan bill that strengthens recent actions by the Trump administration.” 

Original co-sponsors of the House bill include: Reps. Nanette Barragán (D-CA), Vern Buchanan (R-FL), Rosa DeLauro (D-CT), Diana Harshbarger (R-TN), and Troy Carter (D-LA). 

The Senate bill is led by: U.S. Senators Cory Booker (D-NJ), Eric Schmitt (R-MO), Rand Paul (R-KY), Angus King (I-ME), Sheldon Whitehouse (D-RI), John Kennedy (R-LA), Richard Blumenthal (D-CT), Ben Ray Luján (D-NM), and Roger Marshall (R-KS). 

Read full bill text here.

###